CBX821819 1..5 Research Article Suppression of cathepsin K biomarker in synovial fluid as a free-drug– driven process Bennett Ma 1 , Gregg Wesolowski 2 , Bin Luo 3 , Traci Lifsted 3 , Keith Wessner 3 , Gary Adamson 1 , Helmut Glantschnig 2 , and Laura S Lubbers 3 Abstract Cathepsin K (CatK) inhibitors exhibited chondroprotective and pain-reducing effects in animal models, however, improvements were relatively modest at dose levels achieving maximal suppression of CatK biomarkers in urine. In this report, a previously characterized CatK inhibitor (MK-1256) is utilized to explore the potential of reduced target engagement and/or suboptimal exposure (free drug) as limiting factors to the pharmacological potential of CatK inhibitors in the knee joint. Following oral administration of MK-1256 at a dose level achieving maximal inhibition of urinary biomarker (helical peptide) in dogs, full suppression of the biomarker in synovial fluid was observed. Subsequent tissue distribution studies conducted in dogs and rabbits revealed that MK-1256 levels in synovial fluid and cartilage were consistent with the free-drug hypothesis. Reasonable projection (within twofold) of drug levels in these tissues can be made based on plasma drug concentration with adjustments for binding factors. These results indicate that the previously observed efficacies in the animal models were not limited by compound distribution or target engagement in the knee tissues. Keywords Cathepsin K, MK-1256, osteoarthritis, synovial fluid, cartilage Date received: 19 April 2018; accepted: 1 December 2018 Introduction Osteoarthritis (OA) is a debilitating disease that is com- monly characterized by joint pain and stiffness stemming from progressive cartilage loss, subchondral bone changes, osteophyte formation, and/or inflamed synovium. 1,2 Exces- sive degradation of tissue matrices is thought to play an important role in the disruption of the joint homeostasis, as evidenced by elevated proteolytic cleavage of collagen observed in osteoarthritic cartilage along with accelerated turnover of subchondral bone and vertical trabeculae. 3 Various hydrolytic enzymes catalyzing the breakdown of joint matrices have been implicated for their roles in OA progression, making them appealing targets for the develop- ment of disease-modifying anti-OA drugs (DMOADs). 1,2 Cathepsin K (CatK), a cysteine protease displaying triple helical collagen hydrolase activity, is capable of disinte- grating collagen type I (in bone) and type II (in cartilage) and aggrecan. 3,4 CatK inhibitors are effective bone antire- sorptive agents for the treatment of osteoporosis in clinical trials, demonstrating improvements in bone mineral density and bone strength with robust reductions in collagen 1 Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., West Point, PA, USA 2 Department of Bone Biology, Merck & Co., West Point, PA, USA 3 Department of Pharmacology, Merck & Co., West Point, PA, USA Corresponding Author: Bennett Ma, Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, WP75B-200, Merck & Co., West Point, PA 19486, USA. Email: bennett_ma@merck.com Journal of Circulating Biomarkers Volume 8: 1–5 ª The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/1849454418821819 journals.sagepub.com/home/cbx Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). https://orcid.org/0000-0002-8494-9875 https://orcid.org/0000-0002-8494-9875 mailto:bennett_ma@merck.com https://sagepub.com/journals-permissions https://doi.org/10.1177/1849454418821819 http://journals.sagepub.com/home/cbx https://us.sagepub.com/en-us/nam/open-access-at-sage degradation biomarkers. 5,6 Early assessments of CatK inhi- bitors as DMOADs in animal models revealed promising chondroprotective and pain-reducing effects. 7–9 However, the improvements were relatively modest (approximately 30–50%) when compared to maximal suppression (approx- imately 60–80%) observed for urinary biomarkers of CatK-mediated collagen degradation. In an attempt to explore the potential of reduced target engagement and/or exposure as limiting factors for the observed efficacy, experiments were conducted to determine biomarker sup- pression and drug concentration at the knee joint using a previously characterized CatK inhibitor MK-1256. 10 Materials and methods In vivo dog and rabbit studies In vivo dog and rabbit studies were conducted in a similar manner as reported previously. 10 Briefly, adult male beagle dogs received a daily oral dose of MK-1256 (at 7, 70, or 700 mg/kg; n ¼ 7 or 8 per dose group) prepared in 0.5% methylcellulose (MC) with 0.25% sodium dodecyl sulfate (SDS) or control vehicle. On day 6, serial plasma samples were collected at 0, 1, 2, 4, 7 and 24 h post-dose with corre- sponding urine samples also collected in the same 24-h period. After the collection of the last plasma and urine samples on day 7, synovial fluid and articular cartilage sam- ples from both knees were immediately harvested following euthanasia of dogs (n ¼ 4) dosed with 700 mg/kg MK-1256 and with control vehicle. Distribution of MK-1256 to syno- vial fluid and articular cartilage was also studied in 9-month- old ovariectomized female New Zealand White rabbits (approximately 3.5 kg body weight; n ¼ 5). An oral dose of 30 mg/kg MK-1256 was administered to the rabbits daily for 4 days, with serial plasma samples collected at 0, 1, 2, 4, 7, and 24 h post-dose on day 4. Immediately following the collection of 24-h plasma sample, rabbits were euthanized and samples of synovial fluid and articular cartilage from both knees were harvested. All animal studies were con- ducted in compliance with IACUC policies. Measurement of biomarker in urine and synovial fluid The bone resorption biomarker helical peptide (HP) in dog urine was measured using an enzyme-linked immu- nosorbent assay followed by normalization to creatinine level determined from the same sample. 10 For synovial fluid, samples were pretreated with bovine hyaluroni- dase (Sigma, St Louis, Missouri, USA; 1 unit per 0.2 mL synovial fluid) at 37�C overnight was performed prior to quantification. Quantitative analysis of MK-1256 in plasma, synovial fluid, and cartilage The concentration of MK-1256 in dog and rabbit plasma was determined by liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis. 10 This method was modified for synovial fluid, with samples diluted 1:10 (w/w) with control plasma prior to quantification. For cartilage harvested from knee joint of dog and rabbit, each milligram of tissue was enzymatically digested with 4 mL of phosphate-buffered saline containing 2 mg/mL each of collagenase (Wako Chemicals, Richmond, Virginia, USA) and hyaluronidase at 37�C for 24 h and then processed with a protein precipitation method followed by LC-MS/MS analysis. Binding of MK-1256 to plasma proteins and to cartilage were performed as described by Ma et al 10 and Wang et al, 11 respectively. Calculations Prediction of drug concentration in synovial fluid and in cartilage was calculated with the following equations ½MK-1256�synovial fluid ¼ ½MK-1256�unbound; plasma Fraction unbound of MK-1256 in synovial fluid ð1Þ ½MK-1256�cartilage ¼½MK-1256�unbound; plasma � cartilage binding factor ð2Þ in which the fraction unbound of MK-1256 in synovial fluid was calculated based on a 2.8-fold difference in protein content between synovial fluid (approximately 25 mg/mL) and plasma (approximately 69 mg/mL), 11–13 and the cartilage binding factor was determined by incuba- tion of MK-1256 with bovine knee cartilage based on the method previously reported. 11 Statistical analyses, includ- ing Student’s t-test, were performed using the Microsoft Excel software package (Redmond, Washington, USA). Results A dose-dependent decrease in urinary helical peptide (HP) level was observed following oral administration of MK- 1256 in dogs (Figure 1(a)). This biomarker for collagen degradation was maximally suppressed on day 6 following a daily dose of MK-1256 at 700 mg/kg. Full suppression of HP in synovial fluid was observed at this dose level (Figure 1(b)), suggesting that MK-1256 exposure to the knee joint was sufficient to achieve full target engagement. Direct measurement of (total) MK-1256 levels in synovial fluid and cartilage revealed lower drug concentrations in these tissues as compared to that in plasma (Table 1), con- sistent with the anticipation that knee tissues exhibit less drug binding as a result of reduced protein content. With the apparent applicability of the free-drug hypothesis with regard to MK-1256 distribution in the knee, prediction of drug concentration in synovial fluid was performed with an 2 Journal of Circulating Biomarkers estimated unbound fraction based on the protein content. Projection of MK-1256 concentration in cartilage was obtained by applying a binding factor determined in vitro. Predicted (total) drug concentrations in synovial fluid and cartilage were in reasonable agreement (within twofold) with the measured values (Table 1). In a distribution study conducted in rabbits receiving a daily dose of 30 mg/kg MK-1256, the prediction drug concentrations in synovial fluid and cartilage were also within twofold of the observed values (Table 1), indicating that the presented approach to predict drug concentrations in the knee tissues is applicable across species. Discussion CatK inhibitors have been suggested to display certain characteristics of DMOADs, exhibiting chondroprotective and pain-reducing effects in various animal models. 7–9 In those cases, modest improvements were observed at dose levels achieving maximal suppression of urinary biomar- kers for collagen degradation. To investigate the potential of reduced target engagement and/or drug level in the knee joint as contributing factors for limited efficacy, experiments were conducted in the current study to mea- sure both the CatK activity biomarker (HP) level and the distribution of a highly selective CatK inhibitor (MK-1256) in the knee. Maximal suppression of urinary biomarker was observed in dogs receiving a daily dose of MK-1256 at 700 mg/kg, consistent with the measured plasma drug concentration (Cavg: 0.52 mM; Table 1) being 43-fold higher than the reported half maximal effective concentration (12 nM). 10 At this dose level, full suppres- sion of HP in synovial fluid was also achieved, suggest- ing that the unbound drug concentrations in synovial fluid and plasma closely resembled each other – a phenomenon that had been observed for several nonsteroidal anti- inflammatory drugs (NSAIDs). 14,15 Synovium is a highly vascularized membrane that encapsulates synovial fluid present in the articular cavity. 14,15 The porous nature of the membrane allows small molecules to diffuse in and out of the joint cavity efficiently. Pharmacokinetic studies conducted in human with intra-articular administration of NSAIDs showed that these compounds efficiently diffused out of the synovial fluid, with half-life values observed in synovial fluid similar to those detected in plasma. 14,15 Applica- tion of the non-compartmental analysis revealed that the area under the concentration–time curve (AUC) mea- sured in synovial fluid obtained after oral administration of NSAIDs was in good agreement with the plasma AUC. Consistent with this observation, the average (total) plasma drug concentrations determined in the current study were in reasonable agreement (within two- fold) with the drug concentrations in synovial fluid after adjusting for protein binding (Table 1). As the unbound drug concentration in synovial fluid approached equili- brium with the unbound fraction in plasma at steady state, full suppression of the biomarker in synovial fluid was observed at the dose level that achieved maximal inhibition of urinary biomarker (Figure 1). While bio- marker and the pharmacodynamics effect of MK-1256 was not directly assessed in articular cartilage, predicted and observed MK-1256 exposure data are congruent with inhibition of CatK in this compartment in dogs and rabbits. Taken together, the presented results in the ani- mal models indicate that CatK biomarker suppression in synovial fluid is a free-drug–driven process. Early human pharmacokinetics studies conducted with NSAIDs showed evidence of applicability of free-drug hypothesis regarding compound distribution to the knee joint. 14 For compounds exhibiting extensive binding to plasma proteins (e.g. protein binding of >98%), drug con- centration in synovial fluid in reference to that in plasma U ri n e H P /C r, μ g /m m o l C r 0 50 100 150 200 Vehicle Control 700 μg/kg 70 μg/kg 7 μg/kg p < 0.001 p < 0.01 p = 0.32 S y y n o v ia l fl u id H P , μ g /L 0 2 4 6 8 10 12 14 Vehicle Control 700 μg/kg p < 0.001 (a) (b) Figure 1. Biomarker suppression in dog urine (a) and synovial fluid (b). Male beagle dogs received a daily oral dose of MK-1256 at 7, 70, or 700 mg/kg (n ¼ 7 or 8). Urine samples were collected on day 6 while synovial fluid samples from both knees were immediately harvested 24 h after the last dose from the dogs in the high-dose group (700 mg/kg) and control group (n ¼ 4 per group). Student’s t-tests were performed and the corresponding p values were reported. Ma et al. 3 should be proportional to the (albumin) protein concentra- tion ratio between these two matrices—an observation that was reported for inhibitors of matrix metalloprotease fol- lowing oral administration of compound to rabbits. 11 With the consideration of a 2.8-fold difference in protein content between synovial fluid and plasma, drug binding to syno- vial fluid can be estimated from the plasma protein binding value determined in vitro. 13 This approach allows a projec- tion of drug concentration in synovial fluid based on plasma drug level when equilibrium of unbound drug is reached between these matrices. Reasonable prediction (within twofold) was observed in the current study as well as data reported by Wang et al. 11 and Day et al., 14 confirm- ing the feasibility of the current approach to estimate drug level in synovial fluid based on plasma drug concentration and the unbound fraction of drug in plasma. In conclusion, the current study confirmed that the dis- tribution of MK-1256 to the knee joint is consistent with the free-drug hypothesis, leading to full suppression of local CatK biomarker in the synovial fluid at the dose level achieving maximal inhibition of urinary biomarker. The drug levels in synovial fluid and cartilage can be reasonably estimated based on plasma drug concentration with adjust- ments for binding factors. These results indicated that the observed efficacies in the animal models of OA were likely not limited by compound distribution or target engagement (i.e. CatK inhibition) in the knee tissues. Declaration of conflicting interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All authors are current or former employees of Merck & Co., who were employed at the time the experiment was con- ducted. The authors alone are responsible for the writing and content of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Merck & Co. ORCID iD Bennett Ma https://orcid.org/0000-0002-8494-9875 References 1. Karsdal MA, Bay-Jensen AC, Lories RJ, et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treat- ments? Ann Rheum Dis 2014; 73: 336–348. 2. Thysen S, Luyten FP, and Lories RJ. Targets, models and challenges in osteoarthritis research. Dis Model Mech 2015; 8: 17–30. 3. Mort JS, Beaudry F, Théroux K, et al. Early cathepsin K degradation of type II collagen in vitro and in vivo in articular cartilage. Osteoarthr Cartil 2016; 24: 1461–1469. 4. Aguda AH, Panwar P, Du X, et al. Structural basis of collagen fiber degradation by cathepsin K. Proc Natl Acad Sci USA 2014; 111: 17474–17479. 5. Cheung AM, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitec- ture, and estimated bone strength. J Bone Miner Res 2014; 29: 1786–1794. 6. Eastell R, Nagase S, Small M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res 2014; 29: 458–466. 7. Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012; 50: 1250–1259. 8. Connor JR, LePage C, Swift BA, et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial med- ial meniscectomy model of osteoarthritis. Osteoarthritis Car- tilage 2009; 17: 1236–1243. 9. McDougall JJ, Schuelert N, and Bowyer J. Cathepsin K inhi- bition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthritis Cartilage 2010; 18: 1355–1357. 10. Ma B, Luo B, Eluer DH, et al. Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis. Naun yn -Schmied eb erg Arch Pharmacol 2017; 390: 435–441. 11. Wang Q, Glasson S, Raut U, et al. In vitro-in vivo correlation on delivery of drug candidates to articular cartilage. Pharm Res 2008; 25: 1641–1646. Table 1. Observed and predicted MK-1256 in plasma, synovial fluid and cartilage in dogs and rabbits. Species (subjects) Dose (mg/kg) Plasmaa concentration (mM) Fraction unbound in plasma (%) Estimated fraction unbound in synovial fluid (%) Predicted synovial fluid concentration (mM) Observed synovial fluid concentration (mM) Cartilage binding factor Predicted cartilage concentration (mM) Observed cartilage concentration (mM) Dog (n ¼ 4) 0.7 0.52 + 0.15 30 54 0.29 0.15 + 0.07 1.2 0.18 0.27 + 0.11 Rabbit (n ¼ 5) 30 2.1 + 0.2 40 65 1.3 0.90 + 0.31 1.2 1.0 1.3 + 0.3 a Reported as mean + standard deviation for average concentration within a 24-h period. 4 Journal of Circulating Biomarkers https://orcid.org/0000-0002-8494-9875 https://orcid.org/0000-0002-8494-9875 https://orcid.org/0000-0002-8494-9875 12. Chen CPC, Hsu CC, Chen RL, et al. Changes of synovial fluid protein concentrations in supra-patellar bursitis patients after the injection of different molecular weights of hyaluro- nic acid. Exp Gerontol 2014; 52: 30–35. 13. Kalvass JC and Maurer TS. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 2002; 23: 327–338. 14. Day RO, McLachlan AJ, Graham GG, et al. Pharmacoki- netics of nonsteriodal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999; 36: 191–210. 15. Larsen C, Østergaard J, Larsen SW, et al. Intra-articular depot formulation principles: role in the management of postopera- tive pain and arthritic disorders. J Pharm Sci 2008; 97: 4622–4654. Ma et al. 5 << /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles true /AutoRotatePages /None /Binding /Left /CalGrayProfile (Gray Gamma 2.2) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Warning /CompatibilityLevel 1.4 /CompressObjects /Off /CompressPages true /ConvertImagesToIndexed true /PassThroughJPEGImages false /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends true /DetectCurves 0.1000 /ColorConversionStrategy /LeaveColorUnchanged /DoThumbnails false /EmbedAllFonts true /EmbedOpenType false /ParseICCProfilesInComments true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams true /MaxSubsetPct 100 /Optimize true /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage true /PreserveDICMYKValues true /PreserveEPSInfo true /PreserveFlatness false /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Remove /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true ] /NeverEmbed [ true ] /AntiAliasColorImages false /CropColorImages false /ColorImageMinResolution 266 /ColorImageMinResolutionPolicy /OK /DownsampleColorImages true /ColorImageDownsampleType /Average /ColorImageResolution 175 /ColorImageDepth -1 /ColorImageMinDownsampleDepth 1 /ColorImageDownsampleThreshold 1.50286 /EncodeColorImages true /ColorImageFilter /DCTEncode /AutoFilterColorImages true /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.40 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.76 /HSamples [2 1 1 2] /VSamples [2 1 1 2] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /CropGrayImages false /GrayImageMinResolution 266 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages true /GrayImageDownsampleType /Average /GrayImageResolution 175 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50286 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.40 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.76 /HSamples [2 1 1 2] /VSamples [2 1 1 2] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /CropMonoImages false /MonoImageMinResolution 900 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages true /MonoImageDownsampleType /Average /MonoImageResolution 175 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50286 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox false /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (U.S. Web Coated \050SWOP\051 v2) /PDFXOutputConditionIdentifier (CGATS TR 001) /PDFXOutputCondition () /PDFXRegistryName (http://www.color.org) /PDFXTrapped /Unknown /CreateJDFFile false /Description << /ENU >> /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ << /AsReaderSpreads false /CropImagesToFrames true /ErrorControl /WarnAndContinue /FlattenerIgnoreSpreadOverrides false /IncludeGuidesGrids false /IncludeNonPrinting false /IncludeSlug false /Namespace [ (Adobe) (InDesign) (4.0) ] /OmitPlacedBitmaps false /OmitPlacedEPS false /OmitPlacedPDF false /SimulateOverprint /Legacy >> << /AllowImageBreaks true /AllowTableBreaks true /ExpandPage false /HonorBaseURL true /HonorRolloverEffect false /IgnoreHTMLPageBreaks false /IncludeHeaderFooter false /MarginOffset [ 0 0 0 0 ] /MetadataAuthor () /MetadataKeywords () /MetadataSubject () /MetadataTitle () /MetricPageSize [ 0 0 ] /MetricUnit /inch /MobileCompatible 0 /Namespace [ (Adobe) (GoLive) (8.0) ] /OpenZoomToHTMLFontSize false /PageOrientation /Portrait /RemoveBackground false /ShrinkContent true /TreatColorsAs /MainMonitorColors /UseEmbeddedProfiles false /UseHTMLTitleAsMetadata true >> << /AddBleedMarks false /AddColorBars false /AddCropMarks false /AddPageInfo false /AddRegMarks false /BleedOffset [ 9 9 9 9 ] /ConvertColors /ConvertToRGB /DestinationProfileName (sRGB IEC61966-2.1) /DestinationProfileSelector /UseName /Downsample16BitImages true /FlattenerPreset << /ClipComplexRegions true /ConvertStrokesToOutlines false /ConvertTextToOutlines false /GradientResolution 300 /LineArtTextResolution 1200 /PresetName ([High Resolution]) /PresetSelector /HighResolution /RasterVectorBalance 1 >> /FormElements true /GenerateStructure false /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles true /MarksOffset 9 /MarksWeight 0.125000 /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PageMarksFile /RomanDefault /PreserveEditing true /UntaggedCMYKHandling /UseDocumentProfile /UntaggedRGBHandling /UseDocumentProfile /UseDocumentBleed false >> ] /SyntheticBoldness 1.000000 >> setdistillerparams << /HWResolution [288 288] /PageSize [612.000 792.000] >> setpagedevice